Settlement Agreement in *Sarah Yules* v. *United States of America*, Civil Action No. 95–10256–WGY (D. Mass.), was preliminarily approved by the United States District Court for the District of Massachusetts on June 19, 1998. Final approval of the proposed Settlement Agreement is subject to the requirements of 28 CFR 50.7.

In this case, Plaintiffs Sarah Yules and Sandra Faxon, acting for themselves and on behalf of proposed class of persons in the Town of Mashpee, Massachusetts, whose drinking water supplies had been contaminated or threatened by pollutants allegedly emanating from the Massachusetts Military Reservation, Barnstable County, Massachusetts (''MMR''), filed suit in 1995 against, among others, the United States Department of Defense and the United States National Guard Bureau (''the federal defendants''). The suit asserted claims under the Comprehensive Environmental Response, Compensation, and Liability Act, the Resource Recovery and Conservation Act, the Federal Clean Water Act, the Federal Tort Claims Act, and state law. Plaintiffs sought, among other things, an injunction requiring the federal defendants to abate any endangerment caused by the alleged discharge of pollutants from the MMR by connecting class members to the public water supply.

The United States and Plaintiffs have now reached agreement on the terms of a settlement of the claims in this case. The Department of Justice will receive written comments on the proposed Settlement Agreement for a period of 30 days from the date of publication of this notice. Comments should be addressed to Joshua E. Swift, U.S. Department of Justice, Environment & Natural Resources Division, Environmental Defense Section, P.O. Box 23986, Washington, DC 20026, and refer to *Sarah Yules* v. *United States of America*, Civil Action No. 95–10246–WGY (D. Mass.), DJ# 90–11–3–1506.

The Settlement Agreement may be examined at the Clerk's Office, United States District Court for the District of Massachusetts, 90 Devonshire Street, Room 607, Boston, Massachusetts (617–223–9152), or at the offices of Plaintiffs' counsel, Shapiro, Haber & Urmy, 75 State Street, Boston, Massachusetts (617–439–3939).

Letitia J. Grishaw,

Chief, Environmental Defense Section, Environmental & Natural Resources Division.

[FR Doc. 98–20259 Filed 7–28–98; 8:45 am]

BILLING CODE 4410–15–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Agency Information Collection Activities: Proposed Collection; Comment Request

ACTION: Notice of Information Collection Under Review; Extension of a currently approved collection; Controlled Substances Import/Export Declaration—DEA Form 236.

This proposed information collection is published to obtain comments from the public and affected agencies. Comments are encouraged and will be accepted until September 28, 1998. Request written comments and suggestions from the public and affected agencies concerning the proposed collection of information.

Your comments should address one or more of the following four points:

1. evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency/component, including whether the information will have practical utility;

2. evaluate the accuracy of the agencies/components estimate of the burden of the proposed collection of information including the validity of the methodology and assumptions used;

3. enhance the quality, utility, and clarity of the information to be collected; and

4. minimum the burden of the collection of information on those who are respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms information technology, e.g., permitting electronic submission of responses.

If you have comments, suggestions, or need copy of the proposed information collection instrument with instructions, if applicable, or additional information, please contact Patricia Good, 202–307–7297, Chief, Policy and Liaison Section, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537.

Overview of this Information

(1) Type of information collection: Extension of a currently approved collection.

(2) The title of form/collection: Controlled Substances Import/Export Declaration—DEA Form 236.

(3) The agency form number, if any, and the applicable component of the Department sponsoring the collection: Form No.: DEA Form 236.

Applicable component of the Department sponsoring the collection: Office of Diversion Control, Drug Enforcement Administration, U.S. Department of Justice.

(4) Affected public who will be asked or required to respond, as well as a brief abstract:

Primary: Business or other for-profit.

Other: None.

Abstract: DEA–236 provide the DEA with control measures over the importation and exportation of controlled substances as required by both domestic and international drug control laws. Affected public consists of businesses or other for profit organizations.

(5) An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond/reply: 230 respondents. 12 responses per year × 15 minutes per response = 3 hrs.

(6) An estimate of the total burden (in hours) associated with the collection: 690 annual burden hours. 230 respondents × 3 hrs. per respondent per year.

If additional information is required contact: Mr. Robert B. Briggs, Clearance Officer, United States Department of Justice, Information Management and Security Staff, Justice Management Division, Suite 850, Washington Center, 1001 G. Street, NW, Washington, DC 20530.

Robert B. Briggs,

Department Clearance Officer, United States Department of Justice.

[FR Doc. 98–20233 Filed 7–28–98; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 13, 1998, American Radiolabeled Chemicals, Inc., 11624 Bowling Green Drive, St. Louis, Missouri 63146, made application by letter to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below.

Drug	Schedule
Dimethyltryptamine (7435)	I
Dihydromorphine (9145)	I
Cocaine (9041)	II
Morphine (9300)	II

The firm plans to bulk manufacture small quantities of the listed controlled substances as radiolabeled compounds.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistance Administrator, Office of Diversion Control, Drug Enforcement Admistration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than September 28, 1998.

Dated: July 16, 1998.

John H. King,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 98–20175 Filed 7–28–98; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances, Registration

By Notice dated January 27, 998, and published in the **Federal Register** on February 14, 1998, (63 FR 18227), Celgene Corporation, 7 Powder Horn Drive, Warren, New Jersey 07059 made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk of manufacturer of the basic classes of controlled substances listed below

Drug	Schedule
2,5-Dimethoxyamphatamine (7396).	I
4-Methoxyamphetamine (7411)	I
Amphetamine (1100)	II
Methylphenidate (1724)	II

The firm plans to manufacture amphetamine for distribution of the bulk active substances to its customers, 4-methoxyamphetamine as an intermediate in the manufacture of a non-controlled substance, methylphenidate for product research and development and 2,5-dimethoxyamphetamine to develop, manufacture and sell compounds to pharmaceutical and agrochemical industries.

DEA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of Celgene Corporation to manufacture the listed controlled substances is consistent with the public interest at this time. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed above is granted.

Dated: July 13, 1998.

John H. King,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 98–20177 Filed 7–28–98; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Registration

By Notice dated April 3, 1998, and published in the **Federal Register** on April 14, 1998, (63 FR 18227), Lilly del Caribe, Inc., Chemical Plant, Kilometer 146.7, State Road 2, Mayaguez, Puerto Rico 00680, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of dextropropoxyphene (9273), a basic class of controlled substance listed in Schedule II.

The firm plans to manufacture bulk product for distribution to its customers.

DEA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of Lilly del Caribe, Inc. to manufacture dextropropoxyphene is consistent with the public interest at this time. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic class of controlled substance listed above is granted.

Dated: July 13, 1998.

John H. King.

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 98–20178 Filed 7–28–98; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Registration

By Notice dated May 6, 1998, and published in the **Federal Register** on May 19, 1998, (63 FR 27588), Lonza Riverside, 900 River Road, Conshohocken, Pennsylvania 19428, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of phenylacetone (8501), a basic class of controlled substance listed in Schedule II.

The firm is importing the phenylacetone to manufacture dextroamphetamine sulfate.

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of Lonza Riverside to import phenylacetone is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. Therefore, pursuant to Section 1008(a) of the Controlled Substances Import and Export Act and in accordance with Title 21, Code of Federal Regulations, § 1301.34, the above firm is granted registration as an importer of the basic class of controlled substance listed above.

Dated: July 14, 1998.

John H. King,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 98–20176 Filed 7–28–98; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 12, 1998, Novartis Pharmaceuticals Corp., Regulatory Compliance, 556 Morris Avenue, Summit, New Jersey 07901, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the Schedule II controlled substance methylphenidate (1724).

The firm plans to manufacture finished product for distribution to its customers

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registered.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administor, Office of Diversion Control, Drug Enforcement